Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative serplulimab in locally advanced resectable thoracic esophageal squamous cell carcinoma with PD-L1 CPS >=10
ChiCTR2400089918Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Pathologic complete response rate. Started Jan 2024; status: recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400089918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089918.